SNDX 241220 40.00P (SNDX241220P40000) Stock Options, News & Quotes

US OptionsDetailed Quotes

SNDX241220P40000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 18 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $33
Moomoo News06:31 ET · Ratings
Barclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)
TipRanks05:55 ET · Ratings
Trending Stocks Today | Micron Technology Falls 14.29% Post-Market
Moomoo News16:35 ET
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $39
Moomoo NewsDec 18 07:31 ET · Ratings
J.P. Morgan Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
TipRanksDec 18 07:06 ET · Ratings
Express News | Syndax Pharmaceuticals Inc : JP Morgan Raises Target Price to $39 From $38
ReutersDec 17 00:20 ET

Comments

Trytosaveabit

Dec 9 06:45

Update

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· 11 mins ago
Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups

Jaguar8

Nov 17 13:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

Jaguar8

Nov 16 16:41

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

Trytosaveabit

Nov 15 18:07

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

Jaguar8

Nov 15 16:32

NEWS RECAP

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation